Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism accelerates crescentic glomerulonephritis
- PMID: 19302241
- PMCID: PMC2759486
- DOI: 10.1111/j.1365-2249.2009.03902.x
Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism accelerates crescentic glomerulonephritis
Abstract
Immunomodulatory enzyme indoleamine 2, 3-dioxygenase (IDO) is one of the initial and rate-limiting enzymes involved in the catabolism of the essential amino acid tryptophan. Via catalysing tryptophan degradation, IDO suppresses adaptive T cell-mediated immunity and plays an important role in various forms of immune tolerance. Its role in T helper type 1 (Th1)-directed, cell-mediated crescentic glomerulonephritis (GN) is still unclear. Therefore, we investigated the activity and role of IDO in crescentic GN using a model of nephrotoxic serum nephritis (NTN), and IDO activity was inhibited by 1-methyl-tryptophan (1-MT) in vivo. Our results showed that activity of IDO, as determined by high performance liquid chromatography analysis of the kynurenine/tryptophan ratio, was increased markedly in the serum and renal tissue of NTN mice, and immunohistochemistry revealed that expression of IDO was up-regulated significantly in glomeruli and renal tubular epithelial cells during NTN. Treatment with 1-MT resulted in significantly exacerbated kidney disease with increased glomerular crescent formation, accumulation of CD4(+)T cells and macrophages in renal tissue, and augmented renal injury compared with phosphate-buffered saline-treated NTN mice, which was associated with enhanced Th1 responses and intrarenal cellular proliferation. These findings suggest that the development of NTN was regulated negatively by increased IDO activity, and IDO might play an important role in the pathogenesis of crescentic GN.
Figures








Similar articles
-
Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice.Arthritis Res Ther. 2007;9(3):R50. doi: 10.1186/ar2205. Arthritis Res Ther. 2007. PMID: 17511858 Free PMC article.
-
Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.J Neurosurg. 2016 Jun;124(6):1594-601. doi: 10.3171/2015.5.JNS141901. Epub 2015 Dec 4. J Neurosurg. 2016. PMID: 26636389
-
Indoleamine 2, 3-dioxygenase (IDO) increases during renal fibrogenesis and its inhibition potentiates TGF-β 1-induced epithelial to mesenchymal transition.BMC Nephrol. 2017 Sep 6;18(1):287. doi: 10.1186/s12882-017-0702-7. BMC Nephrol. 2017. PMID: 28877670 Free PMC article.
-
Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.Int J Biochem Cell Biol. 2009 Mar;41(3):467-71. doi: 10.1016/j.biocel.2008.01.005. Epub 2008 Jan 11. Int J Biochem Cell Biol. 2009. PMID: 18282734 Review.
-
Implications of IFN-gamma-mediated tryptophan catabolism on solid organ transplantation.Curr Drug Metab. 2007 Apr;8(3):273-82. doi: 10.2174/138920007780362536. Curr Drug Metab. 2007. PMID: 17430115 Review.
Cited by
-
Amino acid metabolism inhibits antibody-driven kidney injury by inducing autophagy.J Immunol. 2015 Jun 15;194(12):5713-24. doi: 10.4049/jimmunol.1500277. Epub 2015 May 15. J Immunol. 2015. PMID: 25980011 Free PMC article.
-
The role of the kynurenine pathway in cardiovascular disease.Front Cardiovasc Med. 2024 May 31;11:1406856. doi: 10.3389/fcvm.2024.1406856. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38883986 Free PMC article. Review.
-
High activity of indoleamine 2,3-dioxygenase is associated with renal insufficiency in Puumala hantavirus induced nephropathia epidemica.J Med Virol. 2011 Apr;83(4):731-7. doi: 10.1002/jmv.22018. J Med Virol. 2011. PMID: 21328391 Free PMC article.
-
Limited Effect of Indolamine 2,3-Dioxygenase Expression and Enzymatic Activity on Lupus-Like Disease in B6.Nba2 Mice.Front Immunol. 2019 Aug 27;10:2017. doi: 10.3389/fimmu.2019.02017. eCollection 2019. Front Immunol. 2019. PMID: 31555267 Free PMC article.
-
Kynurenine pathway in kidney diseases.Pharmacol Rep. 2022 Feb;74(1):27-39. doi: 10.1007/s43440-021-00329-w. Epub 2021 Oct 6. Pharmacol Rep. 2022. PMID: 34617264 Free PMC article. Review.
References
-
- Lou YH. Anti-GBM glomerulonephritis: a T cell-mediated autoimmune disease? Arch Immunol Ther Exp. 2004;52:96–103. - PubMed
-
- Kitching AR, Ru Huang X, Turner AL, Tipping PG, Dunn AR, Holdsworth SR. The requirement for granulocyte–macrophage colony-stimulating factor and granulocyte colony-stimulating factor in leukocyte-mediated immune glomerular injury. J Am Soc Nephrol. 2002;13:350–8. - PubMed
-
- Tipping PG, Holdsworth SR. T cells in crescentic glomerulonephritis. J Am Soc Nephrol. 2006;17:1253–63. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials